BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Pharm Country

  Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

  The Lupus Research Alliance today announced the first clinical trials to be conducted through its LuCIN aimed at discovering new treatments for the millions of people around the globe living with lupus.

  October 31, 2017

   · 

  4 min read
• Drug Development

  Mithra Completes Recruitment for Estelle Phase III Study in US & Canada

  Mithra today announces the completion of recruitment in the E4 Freedom Phase III study of Estelle in the US and Canada. Estelle is Mithra’s combined oral contraceptive candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone.

  October 31, 2017

   · 

  2 min read
• Business

  AZTherapies Appoints Karen Reeves, MD As President and CMO

  Former Pfizer executive joins AZTherapies.

  October 31, 2017

   · 

  5 min read
• 

  Deals

  Sterigenics Scoops Up Toxikon’s European Laboratory Biz for Undisclosed Sum

  This acquisition provides a more comprehensive service offering and a platform for growth for Sterigenics’ Nelson Labs business.

  October 31, 2017

   · 

  4 min read
• Deals

  Medicure Acquires Exclusive License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  Medicure has acquired an exclusive license to sell and market PREXXARTAN (valsartan) oral solution in the U.S. and its territories from Carme for a seven year term with extensions to the term available.

  October 31, 2017

   · 

  4 min read
• Business

  Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.Based Financial Markets

  Nektar Therapeutics will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017, after the close of U.S.based financial markets.

  October 31, 2017

   · 

  1 min read
• Business

  Medicure Acquires License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  Under terms of the agreement, Medicure obtains exclusive rights in the United States and territories to develop, manufacture and market PREXXARTAN for a seven year term, with potential extensions to the term available.

  October 31, 2017

   · 

  2 min read
• Business

  OMRON Increases Net Earnings 91.2% to JPY30.3 Billion on Solid Gains in Core Industrial Automation Business

  Net sales for the period increased 10.5%, to JPY410.5 billion.

  October 31, 2017

   · 

  3 min read
• Drug Development

  Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

  Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3.

  October 31, 2017

   · 

  8 min read
• Drug Development

  DelMar Pharma Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

  DelMar presented a poster entitled “DNA Damaging Agent Dianhydrogalactitol (VAL-083) Targets Homologous Repair (HR) Pathway and Suggests Combination Therapy with topoisomerase inhibitors and PARP inhibitors.”

  October 31, 2017

   · 

  6 min read